Metastatic breast cancer patients receiving oral anti-cancer treatment: an audit of practice using CDK 4/6 therapy
Intended for healthcare professionals
Evidence and practice    

Metastatic breast cancer patients receiving oral anti-cancer treatment: an audit of practice using CDK 4/6 therapy

Elaine Tomlins Nurse consultant, Royal Marsden NHS Foundation Trust, Sutton, England
Kate Edridge Advanced nurse practitioner, University Hospital Southampton, Southampton NHS Foundation Trust, Southampton, England

Why you should read this article:
  • To understand the global effect of breast cancer on women

  • To learn how the management of metastatic breast cancer remains challenging

  • To keep up to date with positive developments in metastatic breast cancer such as a new class of anticancer drugs known as cyclin-dependent kinase 4 and 6 inhibitors

Breast cancer is the most common cancer in women worldwide, with more than two million new cases diagnosed in 2018. Overall survival rates for breast cancer vary globally, but in general they have improved, and in the UK, they have doubled over the past 40 years. In England, around 85% of women diagnosed with breast cancer survive for five years or more, and when diagnosed at its earliest stage, 98% of women survive for five years or more. However, this falls to 26% when breast cancer is diagnosed at its latest stage, known as stage IV or metastatic breast cancer. The low survival rate for metastatic breast cancer is in part because management of the condition remains challenging. However, there have been some positive developments for patients with metastatic breast cancer in the form of a new class of anticancer drugs known as cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors. This article describes a service audit at an NHS trust in England investigating current practice regarding the use of CDK 4/6 inhibitors.

Cancer Nursing Practice. doi: 10.7748/cnp.2022.e1779

Peer review

This article has been subject to external double-blind peer review and checked for plagiarism using automated software

Correspondence

elaine.tomlins@rmh.nhs.uk

Conflict of interest

None declared

Tomlins E, Edridge K (2022) Metastatic breast cancer patients receiving oral anti-cancer treatment: an audit of practice using CDK 4/6 therapy. Cancer Nursing Practice. doi: 10.7748/cnp.2022.e1779

Published online: 18 January 2022

Want to read more?

Already subscribed? Log in

OR

Unlock full access to RCNi Plus today

Save over 50% on your first 3 months

Your subscription package includes:
  • Unlimited online access to all 10 RCNi Journals and their archives
  • Customisable dashboard featuring 200+ topics
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests
Subscribe
RCN student member? Try Nursing Standard Student

Alternatively, you can purchase access to this article for the next seven days. Buy now

Or